2686 Middlefield Road, Suite C
33 articles with Natera, Inc.
Natera Receives Final Medicare Coverage for its Signatera™ MRD Test in Stage II-III Colorectal Cancer
Creates patient access to first-of-its-kind, personalized ctDNA test to inform adjuvant treatment decisions and detect recurrence earlier than standard diagnostic tools
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, filed suit yesterday against ArcherDX, Inc. for infringement of Natera's U.S. Patent No. 10,731,220 (the "'220 Patent"). The complaint was filed in the U.S. District Court of Delaware .
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, has received the Force for Change Illuminator award from LWE, accepted by Sheetal Parmar , Natera's VP of Medical Affairs.
Natera Announces Clinical Data at ESMO GI Supporting Personalized ctDNA Testing for Oligometastatic Colorectal Cancer (CRC) Patients
Studies show Signatera's accuracy in identifying 100% of stage IV oligometastatic CRC patients in a pre-surgical setting, and the clinical utility of Signatera in optimizing post-surgical treatment decisions for patients with Stage II-III CRC and stage IV oligometastatic CRC [07-July-2020] SAN CARLOS, Calif. , July 7, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTR
Data Presented at ASCO Shows Natera's Signatera Test Detects Immunotherapy Treatment Response in Metastatic Cancers
Results Support Use of New Blood Test as Surrogate Endpoint in Clinical Trials Assessing Immune Checkpoint Inhibitor Effectiveness
Natera, Inc. reported financial results for the first quarter ended March 31, 2019 and provided an update on recent business progress.
Signatera™ Blood Test Detects Bladder Cancer Relapse Up to Eight Months Earlier Than Current Clinical Standards
Journal of Clinical Oncology Study Shows Natera's Test is Highly Prognostic and Effective for Recurrence Detection
Natera, Inc. (NASDAQ: NTRA) today announced that the U.S. Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its Signatera™ test for use in the post-surgical detection and quantification of circulating tumor DNA (ctDNA) in the blood of patients previously diagnosed with certain types of cancer and in combination with certain drugs
Natera, Inc. announced that it will release results for its first quarter ended March 31, 2019, after the market close on May 9, 2019.
Natera, Inc. announced the pricing of its underwritten public offering of 5,263,158 shares of its common stock at a price to the public of $19.00 per share.
Natera, Inc., a global leader in cell-free DNA testing, announced the launch of a proposed follow-on public offering of $100,000,000 of shares of its common stock.
Natera to Partner with AMAL Therapeutics on Clinical Trial Using Signatera MRD Test to Assess Treatment Response to Colorectal Cancer Vaccine
New Clinical Trial Adds to Growing Number of Studies Supporting Use of Signatera as a Potential Surrogate Endpoint
Natera, Inc., a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, reported financial results for the fourth quarter and year ended December 31, 2018, and provided an update on recent business progress.
Natera and BGI Genomics Announce $50M Partnership to Commercialize Signatera Oncology Test in China and to Develop Reproductive Health Tests in Select Markets on BGI's DNBseq™ Technology Platform
Partnership marks significant milestone for Natera in monetizing its Signatera MRD test and for BGI Genomics a strong endorsement of its DNBseq™ technology platform by a leader in cell-free DNA genetic testing
In the news release, Natera, Inc. Announces Fourth Quarter and Fiscal 2018 Earnings Conference Call, issued 05-Mar-2019 by Natera, Inc.
Natera Announces Publication of Analytical Validation Study Demonstrating Superior Precision of Its Kidney Transplant Rejection Assay
Core Technology Delivers Superior Analytical Performance, Underpins Outstanding Clinical Performance
Natera Presents Outcomes Data at SMFM Annual Meeting Showing Strong Clinical Performance of Its SNP-Based Non-Invasive Prenatal Test
Study Shows High Positive Predictive Values in Detecting Common Chromosomal Aneuploidies in All Women, Including Women Under 35 Years of Age
Agreement Enhances Commercial Presence in Organ Transplant Centers
Natera Announces Publication of Kidney Transplant Validation Study, Demonstrating Superior Data in Detection of Clinical and Subclinical Rejection
Represents Successful Achievement of All 2018 Commercialization Milestones, on Path to 2019 Launch
Represents Key Reimbursement Milestone In Line with Planned Clinical Launch